<国家中医药管理局科技司关于2021年度中医药科学技术研究专项部分课题验收结果的通知>Gelonghui, February 19, Guizhou Bailing (002424.SZ) announced that the company (recently received the “Notice on Forwarding” from the Guizhou Provincial Administration of Traditional Chinese Medicine), according to the “Notice of the Science and Technology Department of the State Administration of Traditional Chinese Medicine on the Acceptance Results of the 2021 Traditional Chinese Medicine Science and Technology Research Special Topics” (China Traditional Chinese Medicine Science and Technology Letter [2024] No. 28), after expert review and combined with the completion of the assessment indicators, the company “Miaoyao Duangning The “Multi-center Clinical Research and Mechanism Discussion on the Prevention of Diabetes and Retinal Complications with Pancreas” (Project No.: GZY-KJS-2021-006) passed the inspection.
贵州百灵(002424.SZ)：“苗药糖宁通络片防治糖尿病及视网膜并发症的多中心临床研究和机制探讨”课题通过验收
Guizhou Bailing (002424.SZ): “Multi-center clinical research and mechanism discussion on the prevention of diabetes and retinal complications with the Miao Drug Tangning Tongluo Tablets” passed the acceptance
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.